Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia
Acute Myeloid Leukaemia (AML) is a rare but serious group of diseases that require critical decision-making for curative treatment. Over the past decade, scientific discovery has revealed dozens of prognostic gene mutations for AML while sequencing costs have plummeted. In this study, we compared th...
Autors principals: | Cressman, S, Karsan, A, Hogge, DE, McPherson, E, Bolbocean, C, Regier, DA, Peacock, SJ |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
Wiley
2016
|
Ítems similars
-
Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada
per: Sonya Cressman, et al.
Publicat: (2020-07-01) -
Acute Myeloid Leukaemia with Plasmacytosis
per: Yasmin Akhtar, Saqib Qayyum Ahmad, Shahid Jamal
Publicat: (2016-12-01) -
Exploring the acute myeloid leukaemias
per: TB Thapa
Publicat: (2013-10-01) -
Secondary acute myeloid leukaemia in children treated for acute lymphoblastic leukaemia.
per: Eden, O, et al.
Publicat: (1998) -
Acute myeloid leukaemia with aberrant expression of pancytokeratin: A diagnostic pitfall
per: Yasin Dhonye, et al.
Publicat: (2023-02-01)